Sign in
HUMA Stock Price, Chart, Stats & News
Humacyte, Inc.
Save
Humacyte, Inc. (HUMA) does not currently pay a dividend.
93.63M
Market cap
–
Current P/E
35.84x
Forward P/E
HUMA chart
Fundamentals
Gross margin | -134.49% |
Operating margin | -5306.04% |
Pretax margin | -786.51% |
Net margin | -2003.58% |
Effective tax rate | – |
ROA | -35.09% |
ROE | -424.76% |
D/E | 20.86x |
Interest coverage ratio | -21.64x |
HUMA valuation
P/E | – |
P/S | 51.97x |
P/B | 34.37x |
P/CF | -1.02x |
P/FCF | -1.00x |
P/OCF | -1.02x |
PEG | -0.60x |
EV multiple | -2.76x |
About
Humacyte, Inc. focuses on developing and manufacturing readily available, implantable human tissues engineered in a laboratory setting. These bioengineered tissues are designed to treat a wide array of diseases and conditions across various anatomical locations and therapeutic fields. The company employs its distinct scientific and proprietary technology platform to produce human acellular vessels (HAVs).
Similar securities
Based on sector and market capitalization
Report issue